TSN-1611

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameTSN-1611
Drug Alias NameTSN-1611
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12D inhibitors
TargetsKRAS G12D
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisLung Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTyligand Bioscience (Shanghai) Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTyligand Pharmaceuticals (Suzhou) LtdTyligand Bioscience (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisLung Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A